Evaluating the prognosis of severe toxoplasmosis in ICU patients
Prognosis of Disseminated and Cerebral Toxoplasmosis Hospitalized in Intensive Care in the Era of PCR Diagnosis - Toxoplasmosis in ICU (TOXIC)
This study looks at how well different treatments work for patients with severe toxoplasmosis in the ICU, especially those with weakened immune systems, to understand their chances of recovery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 100 Years |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris Academic / other |
| Locations | 1 site (Paris, France) |
| Trial ID | NCT06305468 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the prognosis of patients with severe toxoplasmosis who are hospitalized in intensive care units, particularly focusing on those with underlying immunosuppression. It will evaluate the impact of various anti-infective treatment regimens and identify clinical-biological and prognostic differences based on the type of immunosuppression. The study utilizes polymerase chain reaction (PCR) diagnostics to improve the accuracy of diagnosis and treatment response evaluation. By analyzing data from patients with disseminated and cerebral forms of toxoplasmosis, the study seeks to fill gaps in existing research regarding treatment efficacy and patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include adult patients hospitalized in intensive care with at least one organ failure and a positive PCR for toxoplasmosis.
Not a fit: Patients who have a post-mortem diagnosis or whose primary outcome data is unavailable will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better prognostic understanding for patients with severe toxoplasmosis.
How similar studies have performed: While there have been studies on toxoplasmosis, this specific focus on severe cases in ICU settings using PCR diagnostics is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient hospitalized in intensive care * At least 1 organ failure (SOFA\> or =2) * PCR toxoplasmosis on CSF, blood, BAL, or bone marrow positive within 7 days before or after admission to ICU Exclusion Criteria: * Post-mortem diagnosis * Primary outcome not available * Patient living informed and not opposed to the reuse of their data in this research.
Where this trial is running
Paris, France
- Cochin hospital — Paris, France, France (Recruiting)
Study contacts
- Principal investigator: Clara Vigneron, MD — Assistance Publique - Hôpitaux de Paris
- Study coordinator: Clara Vigneron, MD
- Email: clara.vigneron@aphp.fr
- Phone: 06 33 14 56 50
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.